Capricor Therapeutics, Inc.（CAPR）财务数据CAPRCapricor Therapeutics, Inc.

Evaluating the bottom line, Capricor Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -73.70%, provide a clear picture of how effectively CAPR converts its operational activities into shareholder value.

In the context of the broader market, CAPR competes directly with industry leaders such as OVID and SPRY. With a market capitalization of $584.88M, it holds a leading position in the sector. When comparing efficiency, CAPR's gross margin of N/A stands against OVID's 100.00% and SPRY's 61.83%. Such benchmarking helps identify whether Capricor Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Capricor's financial performance shows a troubling trend with negative net income consistently reported, including a net income of -40,733,654 USD for Q2 2026, and a gross margin of 100% in Q4 2024 that has not been maintained in subsequent quarters.